These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 2861432)

  • 1. HTLV-III antibodies after hepatitis B vaccination.
    Kessler H; Chase R; Harris A; Jensen D; Levin S
    Lancet; 1985 Jun; 1(8444):1506-7. PubMed ID: 2861432
    [No Abstract]   [Full Text] [Related]  

  • 2. Absence of antibodies to HTLV-III in health workers after hepatitis B vaccination.
    Dienstag JL; Werner BG; McLane MF; Snydman DR; Grady GF; Craven DE; Crumpacker CS; Polk BF; Platt R; Allan J
    JAMA; 1985 Aug 23-30; 254(8):1064-6. PubMed ID: 2991619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of the hepatitis B vaccine.
    Stevens CE; Taylor PE; Rubinstein P; Ting RC; Bodner AJ; Sarngadharan MG; Gallo RC
    N Engl J Med; 1985 Feb; 312(6):375-6. PubMed ID: 2982093
    [No Abstract]   [Full Text] [Related]  

  • 4. AIDS virus antibody in polytransfused dialysis patients vaccinated against hepatitis B.
    Desmyter J; Reynders M; Goubau P
    Br Med J (Clin Res Ed); 1986 Aug; 293(6546):537. PubMed ID: 3019458
    [No Abstract]   [Full Text] [Related]  

  • 5. No HTLV-III antibodies after HBV vaccination.
    Muylle L; Vranckx P; Peetermans ME
    N Engl J Med; 1986 Feb; 314(9):581. PubMed ID: 2935739
    [No Abstract]   [Full Text] [Related]  

  • 6. [LAV/HTLV III antibody in patients with acute hepatitis B 1975-1984].
    Arendrup M; Lindhardt BO; Krogsgaard K; Gaub J; Nielsen JO
    Ugeskr Laeger; 1986 Mar; 148(14):825-8. PubMed ID: 3010525
    [No Abstract]   [Full Text] [Related]  

  • 7. [Increase in the prevalence of antibodies against LAV/HTLV III in drug addicts in West Germany].
    Zoulek G; Gürtler L; Eberle J; Lorbeer B; Deinhardt F
    Dtsch Med Wochenschr; 1986 Apr; 111(15):567-70. PubMed ID: 3007065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous drug abuse and the accident and emergency department: AIDS (HTLV-III) antibodies and hepatitis B markers.
    Dunlop MG; Steedman DJ; Peutherer JF
    Arch Emerg Med; 1986 Dec; 3(4):257-9. PubMed ID: 3026414
    [No Abstract]   [Full Text] [Related]  

  • 9. The safety of the hepatitis B vaccine. Inactivation of the AIDS virus during routine vaccine manufacture.
    Francis DP; Feorino PM; McDougal S; Warfield D; Getchell J; Cabradilla C; Tong M; Miller WJ; Schultz LD; Bailey FJ
    JAMA; 1986 Aug; 256(7):869-72. PubMed ID: 3016352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HTLV-I and HTLV-III antibodies and tropical spastic paraparesis.
    Rodgers-Johnson P; Gajdusek DC; Morgan OS; Zaninovic V; Sarin PS; Graham DS
    Lancet; 1985 Nov; 2(8466):1247-8. PubMed ID: 2866324
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety of immunoglobulin preparation containing anti-HTLV-III.
    Tedder RS; Uttley A; Cheingsong-Popov R
    Lancet; 1985 Apr; 1(8432):815. PubMed ID: 2858686
    [No Abstract]   [Full Text] [Related]  

  • 12. Evidence for a 1980 HTLV-III infection in a currently asymptomatic B hemophiliac in Italy.
    Varnier OE; Melioli G; Merli A; Schito GC; Tudor G; Boeri E; Molinari AC; Mori PG
    JAMA; 1985 Sep; 254(11):1449-50. PubMed ID: 2993685
    [No Abstract]   [Full Text] [Related]  

  • 13. HTLV-III antibody in East Africa.
    N Engl J Med; 1986 Jul; 315(4):259-60. PubMed ID: 3014335
    [No Abstract]   [Full Text] [Related]  

  • 14. Antibodies to HTLV-III in Haitian immigrants in French Guiana.
    Gazzolo L; Gessain A; Robin Y; Robert-Guroff M; de-Thé G
    N Engl J Med; 1984 Nov; 311(19):1252-3. PubMed ID: 6092952
    [No Abstract]   [Full Text] [Related]  

  • 15. [Anti-HTLV-III/LAV antibodies in hematology reactives].
    Aznar JA; Monzó E; Mayans J; Granda D; Hurtado F; Curats R
    Sangre (Barc); 1986; 31(2):215-7. PubMed ID: 3014670
    [No Abstract]   [Full Text] [Related]  

  • 16. [Research on anti-HTLV-III antibodies: validity of methods].
    Achilli G; Cattaneo E
    Riv Emoter Immunoematol; 1985; 32(2):190-4. PubMed ID: 3003877
    [No Abstract]   [Full Text] [Related]  

  • 17. [Laboratory results in the evaluation of anti HTLV-III in subjects at risk].
    Maschio C; Colangeli S; Rughetti A; Fonzi D; Barnabei R; Ciccarella A
    Riv Emoter Immunoematol; 1985; 32(3):302-6. PubMed ID: 3008301
    [No Abstract]   [Full Text] [Related]  

  • 18. [HTLV-III in patients in a hemodialysis program].
    Cuxart M; Salas M; Aubia J; Lloveras J
    Med Clin (Barc); 1986 Apr; 86(14):611. PubMed ID: 3014239
    [No Abstract]   [Full Text] [Related]  

  • 19. HTLV-I antibodies and lymphoproliferative disease of granular lymphocytes.
    Pandolfi F; Shriver K; Scarselli E; Fiorelli V; Semenzato G; Zambello R; Chisesi T; de Rossi G; Strong DM
    Lancet; 1987 Dec; 2(8574):1527. PubMed ID: 2892087
    [No Abstract]   [Full Text] [Related]  

  • 20. [Significance of anti-HTLV-III antibodies].
    Gerna G
    Riv Emoter Immunoematol; 1985; 32(2):195-7. PubMed ID: 3003878
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.